TB-500 Dosage Calculator

How TB-500 Dosage Calculation Works

This TB 500 dosage calculator (TB-500) converts your loading or maintenance dose in mg into the exact insulin syringe units to draw. TB-500 is supplied as a lyophilized powder and reconstituted with bacteriostatic water (BAC water) before subcutaneous injection. Once reconstituted, the solution has a concentration in mcg/mL. To draw the correct dose on an insulin syringe, you convert your milligram dose to syringe units using that concentration.

1. Concentration (mcg/mL) = Vial size (mg) × 1,000 ÷ BAC water added (mL)
2. Units to draw = (Target dose in mcg ÷ Concentration) × 100 for U-100 syringe

Example: 10 mg vial + 2 mL BAC water = 5,000 mcg/mL. A 2 mg dose (2,000 mcg) = 2,000 ÷ 5,000 × 100 = 40 units on U-100 (0.40 mL). A 2.5 mg loading dose = 50 units (0.50 mL). Enter your values above for an instant result.

TB-500 Loading and Maintenance Dose Reference

TB-500 protocols use a loading phase to rapidly establish tissue-level peptide exposure, followed by a lower maintenance dose. Using a 10 mg vial with 2 mL BAC water (5,000 mcg/mL):

• 2 mg/injection (loading): 40 units on U-100 — 0.40 mL
• 2.5 mg/injection (loading): 50 units on U-100 — 0.50 mL
• Loading phase: 2–2.5 mg × 2–3 injections/week for 4–6 weeks
• Maintenance phase: 2 mg × 1 injection/week

Use the peptide reconstitution calculator to model different BAC water volumes and see how they affect your draw volume per dose.

Choosing BAC Water Volume for TB-500

TB-500 doses are in the milligram range, similar to GLP-1 peptides. Common reconstitution options for a 10 mg vial:

• 2 mL BAC water: 5,000 mcg/mL — 2 mg dose = 40 units; 2.5 mg = 50 units.
• 4 mL BAC water: 2,500 mcg/mL — 2 mg dose = 80 units; 2.5 mg = 100 units. Most common.

Most users prefer 4 mL BAC water, which keeps draws in the 80–100 unit range — easy to read precisely on a standard 1 mL insulin syringe.

TB-500 vs. BPC-157

TB-500 and BPC-157 are frequently combined in research stacks. Key differences: BPC-157 is a 15-amino-acid peptide dosed in micrograms (250–500 mcg/day), while TB-500 is dosed in milligrams (2–2.5 mg per injection). BPC-157 is typically injected daily; TB-500 is injected 2–3 times per week during loading. The two peptides are thought to work through complementary pathways and are often used together. See the BPC-157 dosage calculator for BPC-157-specific defaults.

U-100 vs. U-40 Syringes

A U-100 syringe marks 100 units per mL (1 unit = 0.01 mL); a U-40 marks 40 units per mL (1 unit = 0.025 mL). Drawing the same number of units on a U-40 syringe delivers 2.5× the volume — and 2.5× the dose — compared to a U-100 at the same vial concentration. U-100 syringes are the US standard and strongly preferred for clarity. Always verify the syringe type printed on the barrel before drawing.

TB-500 Benefits and Research

TB-500 is a synthetic analog of Thymosin Beta-4, a naturally occurring peptide found in virtually all human and animal cells. Its primary biological role is regulating actin — a structural protein essential for cell shape, movement, and division. By promoting actin polymerization and cell migration, TB-500 supports the movement of repair cells (fibroblasts, endothelial cells, macrophages) into damaged tissue, which is the foundational step in any healing cascade.

Animal research supports TB-500 for wound healing acceleration, angiogenesis (new blood vessel formation), muscle fiber repair after injury, and reduction of inflammatory markers. In one rodent model, TB-500-treated wound sites showed measurably faster re-epithelialization and collagen deposition compared to controls. Anti-inflammatory effects were observed through reduced TNF-alpha and IL-6 expression. No human clinical trials exist; all human data is self-reported.

• Wound healing: accelerated re-epithelialization and collagen deposition in animal models
• Muscle repair: improved regeneration in muscle injury models; commonly reported by users post-strain or tear
• Angiogenesis: promotes new blood vessel formation to support oxygen and nutrient delivery to healing tissue
• Anti-inflammatory: reduction in TNF-alpha and IL-6 in preclinical studies
• Flexibility: self-reported improvement in joint and connective tissue flexibility, possibly linked to reduced inflammation

TB-500 is frequently stacked with BPC-157. The two peptides are thought to work through complementary pathways — BPC-157 primarily via growth factor upregulation and GH receptor sensitization; TB-500 via actin-mediated cell migration and angiogenesis. See the BPC-157 dosage calculator for BPC-157 dosing details.

TB-500 Side Effects and Safety

TB-500 has a well-tolerated safety profile in animal research, with no significant organ toxicity observed at multiples of typical research doses. Human self-reported side effects are generally mild and transient. As with all research peptides, no human clinical safety data from controlled trials exists.

• Fatigue or lethargy — the most commonly reported side effect; typically occurs in the first 24–48 hours after injection and resolves on its own
• Headache — mild, transient; reported by a minority of users, usually after the first few injections
• Injection site reactions — pain, swelling, or erythema at the injection site; rotate sites to minimize
• Nausea — rare; typically mild and self-limiting
• Unknown long-term effects — no multi-year human studies; long-term safety has not been established

TB-500 is not FDA-approved for human use and is available as a research chemical. Always consult a licensed healthcare provider before use, particularly if you have a history of cancer or autoimmune conditions — TB-500's pro-angiogenic properties are a theoretical concern in the context of malignancy, though no clinical evidence supports this risk at research doses.

Storage and Safe Handling

Reconstituted TB-500 should be refrigerated at 2–8°C and used within 28 days. Do not freeze reconstituted peptide. Lyophilized powder should be stored frozen at −20°C for long-term storage. Always use aseptic technique: wipe the vial stopper with an alcohol swab before each draw, and use a fresh needle for every injection. Dispose of needles and syringes in a puncture-resistant sharps container.